# Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

> **NCT01494805** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lions Eye Institute, Perth, Western Australia** · enrollment: 40 (actual)

## Conditions studied

- Macular Degeneration
- Age-related Maculopathies
- Age-related Maculopathy
- Maculopathies,Age-related
- Maculopathy,Age-related
- Retinal Degeneration
- Retinal Neovascularization
- Eye Diseases

## Interventions

- **BIOLOGICAL:** rAAV.sFlt-1
- **BIOLOGICAL:** rAAV.sFlt-1
- **OTHER:** Control (ranibizumab alone)

## Key facts

- **NCT ID:** NCT01494805
- **Lead sponsor:** Lions Eye Institute, Perth, Western Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2017-05
- **Final completion:** 2017-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494805, "Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01494805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*